Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Dylan J MartiniSubir GoyalYuan LiuSean T EvansT Anders OlsenKatherine CaseBenjamin L MagodJacqueline T BrownLauren YantorniGreta Anne RusslerSarah CaulfieldJamie M GoldmanBassel NazhaWayne B HarrisHaydn T KissickViraj A MasterOmer KucukBradley C CarthonMehmet Asim BilenPublished in: The oncologist (2021)
This study found that early onset immune-related adverse events (irAEs) are associated with significantly improved clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). In this site-specific irAE analysis, endocrine irAEs, particularly thyroid irAEs, were significantly associated with improved clinical outcomes. These results have implications for practicing medical oncologists given the increasing use of ICIs for the treatment of mRCC. Importantly, these results suggest that early irAEs and thyroid irAEs at any time on treatment with ICIs may be clinical biomarkers of clinical outcomes in patients with mRCC treated with ICIs.